2 weeks Ago By ABMN Staff
Dimensional Fund Advisors LP cut its position in Axonics, Inc. ( NASDAQ:AXNX – Free Report ) by 0.6% during the 2nd quarter, according to the company in its most recent disclosure with the SEC.
The firm owned 842,949 shares of the company’s stock after selling 5,397 shares during the period. Dimensional Fund Advisors LP’s holdings in Axonics were worth $56,672,000 at the end of the most recent reporting period. Several other hedge funds also recently bought and sold shares of the company.
Alpine Associates Management Inc. raised its holdings in Axonics by 16.2% in the second quarter.
Alpine Associates Management Inc. now owns 2,108,871 shares of the company’s stock worth $141,779,000 after purchasing an additional 294,100 shares during the period. Magnetar Financial LLC raised its holdings in Axonics by 218.
3% in the first quarter. Magnetar Financial LLC now owns 1,146,019 shares of the company’s stock worth $79,041,000 after purchasing an additional 785,981 shares during the period. KRYGER CAPITAL Ltd acquired a new stake in Axonics in the first quarter worth $65,211,000.
Wasatch Advisors LP raised its holdings in Axonics by 0.7% in the fourth quarter. Wasatch Advisors LP now owns 704,521 shares of the company’s stock worth $43,842,000 after purchasing an additional 5,046 shares during the period.
Finally, Goldman Sachs Group Inc. raised its holdings in Axonics by 6.9% in the fourth quarter.
Goldman Sachs Group Inc. now owns 621,570 shares of the company’s stock worth $38,680,000 after purchasing an additional 40,306 shares during the period. 99.
48% of the stock is currently owned by institutional investors and hedge funds. Analyst Upgrades and Downgrades Separately, Needham & Company LLC reiterated a “hold” rating on shares of Axonics in a report on Monday, August 5th. Eight research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock.
According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $69.57. Axonics Stock Down 0.
1 % Shares of AXNX stock opened at $69.45 on Friday. The firm has a fifty day moving average of $68.
82 and a 200-day moving average of $68.01. Axonics, Inc.
has a 12-month low of $48.30 and a 12-month high of $69.91.
The company has a market capitalization of $3.54 billion, a price-to-earnings ratio of -217.03 and a beta of 0.
81. Axonics ( NASDAQ:AXNX – Get Free Report ) last issued its quarterly earnings data on Thursday, August 1st. The company reported $0.
13 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.10 by $0.03.
The company had revenue of $114.57 million during the quarter, compared to the consensus estimate of $112.83 million.
Axonics had a negative net margin of 0.42% and a negative return on equity of 0.27%.
The firm’s revenue was up 23.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.
15) earnings per share. On average, equities analysts expect that Axonics, Inc. will post 0.
24 EPS for the current year. Axonics Profile ( Free Report ) Axonics, Inc, a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI.
See Also Want to see what other hedge funds are holding AXNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Axonics, Inc. ( NASDAQ:AXNX – Free Report ).
Receive News & Ratings for Axonics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axonics and related companies with MarketBeat.com's FREE daily email newsletter ..
